Skip to main content

What the FDA labels say about taking them together

Prazosin and pretomanid

Pretomanid's FDA label of November 15, 2024 names prazosin in its drug interactions section; the prazosin label PlainMeds reads does not name pretomanid. The pretomanid label: “Therefore, it cannot be excluded that co-administration of pretomanid with sensitive OATP1B3 substrates (e.g., valsartan, statins), BCRP substrates and P-gp substrates may increase their exposure.”

Check it at the source: the prazosin FDA label on DailyMed (effective March 6, 2026, Prasco Laboratories); the pretomanid FDA label on DailyMed (effective November 15, 2024, Viatris Specialty LLC).

What does the prazosin label say about pretomanid?

Prazosin's label (effective March 6, 2026) does not name pretomanid in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Prazosin Hydrochloride), NDA017442 (Pfizer), as published by Prasco Laboratories, effective March 6, 2026 (SPL set cbe89216-7dea-43d7-b12e-44ccfb69af3d), via openFDA; the full label on DailyMed

What does the pretomanid label say about prazosin?

Pretomanid label, drug interactions

Therefore, it cannot be excluded that co-administration of pretomanid with sensitive OATP1B3 substrates (e.g., valsartan, statins), BCRP substrates (e.g., rosuvastatin, prazosin, glyburide, sulfasalazine) and P-gp substrates (e.g., digoxin, dabigatran etexilate, verapamil) may increase their exposure.

Source: FDA drug label (Pretomanid), NDA212862 (Mylan Ireland Ltd), as published by Viatris Specialty LLC, effective November 15, 2024 (SPL set f1906fc9-cb3c-4e13-8a4a-da76100c1bf3), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

33Prazosin generic labelers
0Pretomanid generic labelers
PrazosinPretomanid
Labeled forHigh blood pressuren/a
Boxed warningNoNo
Pharmacy cost (NADAC)$0.0842 per capsule 1 mg capsulen/a
Shortage nowA presentation being discontinuedNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?